Human genetics

PerkinElmer and Honeycomb Biotechnologies Launch the HIVE scRNAseq Solution for Single-Cell Analysis

Retrieved on: 
Lunedì, Ottobre 18, 2021
Biotechnology, Technology, Health, General Health, Pharmaceutical, Medical Devices, Research, Genetics, Science, Hardware, Clinical Trials, Food, Cell, HIVE, Technology, Longevity, American Society of Human Genetics, Time, Solution, RNA-Seq, Neuron, ASHG, Laboratory, Therapy, NYSE, Multimedia, Disease, Granulocyte, Health, Nephron, Honeycomb, Single-cell analysis, Science, Human genetics, Broad Institute, Society, Collection, Quality of life, Company, Massachusetts, Hepatocyte, PKI, PerkinElmer, Genomics, Massachusetts Institute of Technology, Cytobrush, Beekeeping, PerkinElmer, Honeycomb Biotechnologies, PERKINELMER, HONEYCOMB BIOTECHNOLOGIES

PerkinElmer, Inc. (NYSE: PKI) and Honeycomb Biotechnologies, Inc. , announced today the commercial launch of the first of its kind HIVETM scRNAseq Solution for single-cell isolation and analysis.

Key Points: 
  • PerkinElmer, Inc. (NYSE: PKI) and Honeycomb Biotechnologies, Inc. , announced today the commercial launch of the first of its kind HIVETM scRNAseq Solution for single-cell isolation and analysis.
  • The HIVE solution requires no specialized instrumentation to use and expands opportunities for laboratories pursuing basic, translational, clinical and preclinical research.
  • The Honeycomb team is pleased to collaborate with PerkinElmer as we release single-cell RNA-Seq as the first HIVE application.
  • The HIVE scRNAseq Solution integrates sample storage into the single-cell workflow, decoupling the site and time of sample collection from sample processing and analysis, said Chief Executive Officer Jim Flanigon, Ph.D. of Honeycomb Biotechnologies.

Leading Researchers Present 24-Plex Digital PCR Assay and Novel Multiplex Applications Uniquely Enabled by Stilla’s 6-Color naica® system

Retrieved on: 
Venerdì, Ottobre 15, 2021
Research, Medical Devices, Infectious Diseases, Genetics, Biotechnology, Health, General Health, Science, Oncology, Food, Technology, Severe acute respiratory syndrome coronavirus 2, American Society of Human Genetics, LinkedIn, National and Kapodistrian University of Athens, Cancer, Doctor of Philosophy, ASHG, Population, Chinese, Infection, YouTube, Efficiency, Multimedia, DNA, Patient, PCR, Human genetics, Society, University, Fred Hutchinson Cancer Research Center, Twitter, Research, Genomics, Genetics, Nucleic acid thermodynamics, Medical imaging, Television

Stilla Technologies , the multiplex digital PCR company, joined researchers from SAGA Diagnostics in presenting a 24-plex digital PCR assay generated on Stillas six-color naica system.

Key Points: 
  • Stilla Technologies , the multiplex digital PCR company, joined researchers from SAGA Diagnostics in presenting a 24-plex digital PCR assay generated on Stillas six-color naica system.
  • View the full release here: https://www.businesswire.com/news/home/20211015005140/en/
    Stillas six-color naica system, the industrys first six-color digital PCR system, answers market needs for higher performance and multiplexing technology.
  • Learn more here: www.stillatechnologies.com/6-color-dpcr (Photo: Business Wire)
    The six-color naica system is the industrys first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market.
  • Stillas groundbreaking Crystal Digital PCR solution, the naica system , is the industrys first digital PCR system featuring six fluorescent channels, providing biomedical researchers and clinicians the highest multiplexing and detection capacity available on the market.

Goldfinch Bio Announces Upcoming Presentations at American Society of Human Genetics (ASHG) 2021 Meeting and American Society of Nephrology’s (ASN) Kidney Week 2021

Retrieved on: 
Venerdì, Ottobre 15, 2021
Health, Genetics, Other Health, Clinical Trials, General Health, Biotechnology, Diabetic nephropathy, Focal segmental glomerulosclerosis, Patient, Diabetes, Kidney, American Society of Human Genetics, Machine learning, Risk, Precision medicine, Adult, Safety, TRPC5, Association, ASHG, CB1, Health information management, Bio, Haplotype, DNA, Kidney disease, Human genetics, Transience, APOL1, Society, ASN, KGA, DN, FSGS, Hope, Quality of life, Animal, Pharmaceutical industry

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced upcoming presentations at the American Society of Human Genetics (ASHG) 2021 Meeting, taking place October 18-22, 2021, and at the American Society of Nephrologys (ASN) Kidney Week 2021, taking place November 4-7, 2021.

Key Points: 
  • Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced upcoming presentations at the American Society of Human Genetics (ASHG) 2021 Meeting, taking place October 18-22, 2021, and at the American Society of Nephrologys (ASN) Kidney Week 2021, taking place November 4-7, 2021.
  • At ASHG, Goldfinch Bio will give an oral presentation showcasing insights revealed by its Kidney Genome Atlas (KGA).
  • The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention.
  • In 2020, Goldfinch Bio was named one of Fierce Biotechs Fierce 15 companies.

Benchmark Genome Study Demonstrates Accuracy of Artificial Intelligence in Rapidly Diagnosing Rare Diseases in Critically Ill Patients

Retrieved on: 
Giovedì, Ottobre 14, 2021
Research, Technology, Medical Devices, Hospitals, Genetics, Software, Biotechnology, Health, Data Management, Science, Ontology, Community health center, Hospital, Genome Medicine, Tartu University Clinic, Technology, Translational Genomics Research Institute, Diagnosis, Time, LinkedIn, Gene, Genetics, University of Kiel, Lists of diseases, Natural language processing, Doctor of Philosophy, Genomics, Degenerative disease, GEM, Schleswig-Holstein, Health, NICU, Human Phenotype Ontology, Intelligence, Multimedia, Disease, Artificial intelligence, Kiel, NLP, Patient, Doctor of Science, Human genetics, Teaching hospital, University, Institute, CEO, Genetic distance, Twitter, Rady, Rady Children's Hospital, Vaccine, Medical device, Pharmaceutical industry, Medicine

In addition, Fabric GEM ranked specific diseases and conditions associated with these genes to assist clinicians in the ultimate diagnosis of each case.

Key Points: 
  • In addition, Fabric GEM ranked specific diseases and conditions associated with these genes to assist clinicians in the ultimate diagnosis of each case.
  • These findings demonstrate how artificial intelligence (AI) can successfully reduce the burden of gene variant review by clinical geneticists.
  • This study provides the rigorous benchmark validation required for its use in the clinic, showcasing how any hospital can bring informed genomics to their patients.
  • The complete study, titled Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases , can be accessed on the Genome Medicine website.

Parse Biosciences Extends RNA-Seq Kit Reach to Australia and New Zealand through Decode Sciences Agreement

Retrieved on: 
Lunedì, Ottobre 11, 2021
Research, Genetics, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, Cell, List of life sciences, Human genetics, Marketing, Industry, Science, Society, Health, Immune system, WTK, CEO, Kidney, Partnership, Technology, Organizational founder, Growth hacking, Genetics, Fine chemical, Tutoring

Under an agreement between the parties, Decode Science has been appointed a distributor of the Parse product portfolio for Australia and New Zealand.

Key Points: 
  • Under an agreement between the parties, Decode Science has been appointed a distributor of the Parse product portfolio for Australia and New Zealand.
  • Decode Science will provide customer service, technical support, sales and marketing, distribution, and related logistical efforts for the Parse Whole Transcriptome Kit (WTK), Cell Fixation Kit, and Nuclei Fixation Kit.
  • The Parse team is elated to include Australia and New Zealand in the global expansion, said Alex Rosenberg, CEO and Cofounder of Parse Biosciences.
  • Decode Science is excited to bring Parse Biosciences to the Australian and New Zealand life science community, said Josh Warburton, Managing Director of Decode Science.

JScreen.org Adds CancerGEN to National Genetic Screening Program Just in Time for Cancer Awareness Months This Fall

Retrieved on: 
Mercoledì, Ottobre 6, 2021
Knowledge, Goal, Cancer, Breast, Oncology, Man, Assistant, Emory University School of Medicine, Hematology, Heredity, CGC, MD, Ovarian cancer, Lists of diseases, Ovary, Gene, MS, Genetic counseling, Woman, Prostate, Awareness, Associate, Risk, Human genetics, Genetics, Breast Cancer Awareness Month, Genetic testing, Skin, Education, Vaccine, Pharmaceutical industry

This not-for-profit home education and genetic screeningprogramstarted in 2013 with reproductive genetic testing called ReproGEN, and now tests for risk for over 40 types of hereditary cancer with the addition of the CancerGEN test.

Key Points: 
  • This not-for-profit home education and genetic screeningprogramstarted in 2013 with reproductive genetic testing called ReproGEN, and now tests for risk for over 40 types of hereditary cancer with the addition of the CancerGEN test.
  • "Making cancer genetic testing accessible is key," said Jane Lowe Meisel, MD, Associate Professor of Hematology and Medical Oncology at Emory University School of Medicine, and medical director for JScreen's cancer program.
  • "Launching our new cancer program and providing convenient and affordable access to cancer genetic testing across the US will help save lives."
  • JScreen believes the combination of education, access to premier genetic screening technologies and personalized, confidential support are the keys to preventing devastating diseases.

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Retrieved on: 
Giovedì, Settembre 23, 2021
ISPAD, Clinical trial, Diamyd Medical, International Society for Pediatric and Adolescent Diabetes, Hyperglycemia, GAD65, Society, Hannelius, ASHG, Diabetes, Patient, Type 1, Glycated hemoglobin, Eli Lilly and Company, Pediatrics, Continuous glucose monitor, International Society of Sculptors, Painters and Gravers, CEO, Blood, Meta-analysis, Company, Adolescence, Congress, Uppsala University Hospital, Human genetics, CGM, Hypoglycemia, Insulin, IIB, HLA, Nasdaq, EASD, Regeneration, Pharmaceutical industry

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

A new analysis that supports the effect of the diabetes vaccine Diamyd® will be presented at a scientific conference on 13 October

Retrieved on: 
Giovedì, Settembre 23, 2021
ISPAD, Clinical trial, Diamyd Medical, International Society for Pediatric and Adolescent Diabetes, Hyperglycemia, GAD65, Society, Hannelius, ASHG, Diabetes, Patient, Type 1, Glycated hemoglobin, Eli Lilly and Company, Pediatrics, Continuous glucose monitor, International Society of Sculptors, Painters and Gravers, CEO, Blood, Meta-analysis, Company, Adolescence, Congress, Uppsala University Hospital, Human genetics, CGM, Hypoglycemia, Insulin, IIB, HLA, Nasdaq, EASD, Regeneration, Pharmaceutical industry

The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.

Key Points: 
  • The analysis is based on data from Continuous Glucose Montitoring (CGM) and will be presented by Professor Johnny Ludvigsson, Principal Investigator of the clinical trial DIAGNODE-2.
  • Complete results will be submitted for publication in a scientific journal later this year.
  • The diabetes vaccine Diamyd is an antigen-specific immunotherapy for the preservation of endogenous insulin production.
  • A vaccine manufacturing facility is being set up in Ume for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd.

Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal Officer

Retrieved on: 
Giovedì, Settembre 23, 2021
Health, Infectious Diseases, General Health, Research, Science, Biotechnology, Biotechnology, Patent, Infection, Therapy, Molecular biology, Investigational New Drug, Molecular and Cellular Biology, Intellectual property, FDA, Patient, Lawsuit, AMR, United States Department of Defense, IP, Principal, University, LLC, Founder, Technology, Human genetics, Genetics, APT, BS, Industry, Johns Hopkins School of Medicine, Human Genome Sciences, Pharmaceutical industry

Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer.

Key Points: 
  • Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer.
  • Were thrilled to welcome Michele to the Adaptive Phage Therapeutics team.
  • Dr. Wales joins Adaptive Phage Therapeutics after serving as the Principal and Founder of InHouse Patent Counsel, LLC where she provided patent and intellectual property counsel for biotechnology companies.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

Dr. Jean Bennett and George Migausky Join REGENXBIO Board of Directors

Retrieved on: 
Martedì, Settembre 7, 2021

REGENXBIO Inc. (Nasdaq: RGNX) today announcedthe appointment of Jean Bennett, M.D., Ph.D., and George Migausky to its Board of Directors, effective September3, 2021.

Key Points: 
  • REGENXBIO Inc. (Nasdaq: RGNX) today announcedthe appointment of Jean Bennett, M.D., Ph.D., and George Migausky to its Board of Directors, effective September3, 2021.
  • "Jean is a renowned and dynamic researcher who has made significant contributions to gene therapy translational studies throughout her career.
  • "I am honored to join the REGENXBIO Board of Directors during this exciting time of important growth for the company," said Mr. Migausky.
  • REGENXBIO also announced that Luke M. Beshar has resigned from its Board of Directors, effective September3, 2021.